company? Let’s change
that.
Don't see your company?
Create a company profileOur team develops simple, efficient procure-to-pay solutions for biotech research organizations as they develop life-saving therapies for the world's most serious health problems. Prendio is proud to play a small part in this important healing mission.
JoVE is the world-leading producer and provider of science video solutions with the mission to improve scientific research and education. Millions of scientists, educators and students at thousands of universities, colleges, hospitals and biopharmaceutical companies worldwide use JoVE for their research, teaching and learning. Our institutional clients comprise over 1,000 universities, colleges, and biopharma companies, including such leaders as Harvard, MIT, Yale, and Stanford.
Headquartered in Boston’s Seaport community, Entrada Therapeutics is a growing biopharmaceutical company innovating to transform the treatment of devastating diseases through intracellular therapeutics. We’re establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), with the potential to engage intracellular targets that have long been considered inaccessible and undruggable. Our EEV™ therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through our proprietary, highly versatile, and modular EEV™ Platform, we are building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology, and diseases of the central nervous system. For more information about Entrada, please visit www.entradatx.com.
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 61,000 staff across a network of over 1,000 independent companies in 59 countries, operating 940 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ revenues have increased by 33% each year (in compound average) to reach €6.7 billion in 2021.
DermBiont’s mission is to become the world’s leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root causes of skin diseases through the development of targeted small molecule therapeutics with well-defined mechanisms of action and biotherapeutics that repair an imbalance of the microbiome. The company’s targeted topical therapeutics pipeline includes SM-020 for the treatment of seborrheic keratosis, SM-030 for the treatment of hyperpigmentation disorders of the skin, and DBI-001 & DBI-002 for the treatment of atopic dermatitis, tinea pedis, and onychomycosis.
SmartLabs is accelerating the pace of scientific discovery by radically transforming the way the world builds and uses lab space. Where lab construction can take 9 to 12 months in the traditional process, we deliver personalized and effective lab workflow environments in about 4 weeks. This huge reduction in time means member teams are starting sooner and results are delivered faster. We continue to compound this time savings with our proactive operational support and ability to pivot and change lab space quickly as member science evolves and lab needs change. We love what we do - our members are shaping the future and we are proud to help them do it! We currently have locations in the MIT area of Cambridge, at Innovation Square in the Boston Seaport, in the hot new development at Boston Landing, and in South San Francisco. Visit our website to request a tour.
Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers. Clasp is developing T cell engagers to match both the specific characteristics of the patient’s immune system and the specific genetics of their tumor, enabling the creation of exquisitely personalized, yet off-the-shelf, therapeutics. Built upon academic research in the labs of Bert Vogelstein and Drew Pardoll at Johns Hopkins University, Clasp is backed by prominent life sciences investors including Catalio Capital Management, Third Rock Ventures and Novo Holdings. The company was launched in March 2024 and is based in Cambridge, MA and Rockville, MD.
At Akili, we’re creating personalized digital therapeutics engineered to directly improve cognitive impairments. Our medicines look and feel like high-end interactive action video games but, unlike typical video games, they are informed by decades of neuroscience and built with proprietary technology developed to target and treat cognitive impairments at their specific sources in the brain. Not only is our medicine designed to target the areas of your brain that need it most, it’s designed specifically for you, adapting based on your individual needs.
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.
Diagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies. The Company's DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal's emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver life-changing therapies to patients including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
Edge Embossing produces disposable plastic parts that become medical devices. Our customers are other biotech companies and researchers who are developing next-generation products for applications like early detection of cancer or HIV or DNA sequencing. We wake up every day knowing we're making the world a better place.